{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT00043797: Phase 2 Interventional Unknown status Diabetic Polyneuropathy
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Lidorestat is a highly potent and selective aldose reductase inhibitor with good oral bioavailability that is reported to improve nerve conduction and reduce cataract formation. Lidorestat reduced mortality rates in hAR transgenic mice. Mice receiving lidorestat had similar survival rates as nonhAR-expressing diabetic mice. Lidorestat treatment did not affect plasma lipids, glucose, or weights of diabetic mice. Drugs such as lidorestat will improve human health by reducing the production of toxic products of the polyol pathway. Lidorestat was developed for the treatment of diabetic complications, including neuropathy, retinopathy, cataracts, nephropathy.
Status:
Investigational
Source:
NCT01103349: Phase 2 Interventional Completed Asthma
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Boehringer Ingelheim is developing BI-671800, an orally administered treatment for seasonal allergic rhinitis and asthma. BI-671800 is an antagonist of the PGD2 receptor, CRTH2. PGD2 stimulates bronchoconstriction and allergic airway inflammation in animal models. Inhibition of CRTH2 may reduce airway inflammatory cells, IL -4, -5, -13 production, serum IgE and airway hyper reactivity. Treatment with BI-671800 in poorly controlled asthmatic patients receiving FP was associated with a significant improvement in FEV1. BI-671800 was well tolerated at a total daily dose of 800 mg for 6 weeks.
Class (Stereo):
CHEMICAL (ACHIRAL)
Fosarilate was studied as an antiviral agent. Information about the current use of this compound is not available.
Status:
Investigational
Source:
NCT03887169: Phase 1/Phase 2 Interventional Completed Pulmonary Alveolar Proteinosis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Homocysteine, an amino acid synthesized intracellularly by removal of the N-methyl group from the essential amino acid methionine. High plasma level of homocysteine is called hyperhomocysteinemia is a clinical biomarker for increased risk of cardiovascular disease, thromboembolic diseases, and myocardial infarction. It was shown, that hyperhomocysteinemia could be an independent risk factor for dementia and Alzheimer's disease. The falling of homocysteine concentrations in response to increasing B-group-vitamin status, have the hope that mental decline, or Alzheimer's disease, could be prevented by dietary modification or food fortification. Besides, homocysteine can behave as an anti-oxidant agent by increasing the antioxidant capacity of the tumor and endothelial cells.
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
There is no much information related to the biological properties of ftaxilide. It is known, that it’s not intended for therapeutic use, but has the antibacterial properties and used as antiseptic.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Ftormetazine was studied as a psychotropic and an antiarrhythmic agent. Information about the current use of this compound is not available.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ciprostene is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Clomoxir (POCA, B 807-27) is a potent inhibitor of mitochondrial fatty acid oxidation at the stage of carnitine palmitoyltransferase I (CPT-I). It acts by the tight binding of POCA-CoA to this enzyme. The compound demonstrated hypoketonaemic and hypoglycaemic activities in fasted normal and diabetic rats.
Status:
Investigational
Source:
NCT01004315: Phase 3 Interventional Completed Overactive Bladder
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ritobegron (KUC 7483) is a selective β3-adrenoceptor agonist that was developed for oral treatment of overactive bladder. It is the prodrug of the active compound KUC-7322. Phase I studies have investigated the pharmacodynamic and pharmacokinetic effects of ritobegron in healthy individuals and patients with spinal cord injury. Ritobegron exhibits a high selectivity for the bladder versus other organs, and decreased intravesical pressure with minimal effects on the cardiovascular system in rats. When administered in combination with organic anion transporter (OAT) inhibitors such as probenecid (primarily used in treating gout and hyperuricemia), the plasma concentration of the active compound KUC-7322 may increase.
Class (Stereo):
CHEMICAL (RACEMIC)
Moxadolen is tricyclo-[5.2.1.0.2.6endo]decenone derivative. Moxadolen pharmacokinetics were investigated after oral application in male Wistar rats. The compound is extensively absorbed and mainly renally eliminated. Within 60 h, 63% of the activity is recovered in urine and feces. After 12 h 27% of the activity is eliminated (application in polyethylene glycol). The highest total concentration of the activity in the plasma is found after 2 h, the highest of the unchanged drug is found after 1 h. The half-life is 2.9 h.
